Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EATON: Nazartinib + Trametinib in EGFR-mutant NSCLC
NCT03516214Phase 1Completed
- Sponsor
- University of Cologne
- Start
- Apr 2018
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of nazartinib in non-small cell lung cancer (NSCLC), sponsored by University of Cologne. Primary endpoint: Incidence of dose-limiting-toxicities at 28 days. Started Apr 2018; status: completed.
02
Drugs
nazartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03516214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516214.